One project aims to collect patients' genomic and molecular information in a database, and another aims to tailor treatments based on patients' molecular profiles.
The Phase 0 trial will assess whether infigratinib can cross the blood-brain barrier to penetrate recurrent high-grade gliomas harboring FGFR genetic alterations.
Presentations at the American Society of Clinical Oncology's virtual annual meeting included new findings relevant to both blood- and spinal fluid-based approaches.
One cohort will involve NSCLC patients with MET exon 14 skipping mutations, while two other cohorts will enroll patients with solid tumors with MET amplifications and fusions.
The company, which recently wrapped enrollment for a Phase II trial in China, is continuing to actively enroll patients in the US trial for the drug despite the COVID-19 pandemic.
The first-in-class VT1021 would treat patients with various cancers whose tumors have high CD36 expression by reprogramming the tumor immune microenvironment.
